Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO) Share Price

Price 165.50p on 07-04-2025 at 18:35:08
Change -14.50p -7.87%
Buy 174.50p
Sell 165.00p
Buy / Sell HEMO Shares
Last Trade: Buy 1,434.00 at 174.2676p
Day's Volume: 33,614
Last Close: 169.75p
Open: 180.00p
ISIN: GB00BQVXM815
Day's Range 165.50p - 180.00p
52wk Range: 0.876p - 420.00p
Market Capitalisation: £7m
VWAP: 172.49496p
Shares in Issue: 4m

Hemogenyx (HEMO) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,434 174.2676p Ordinary
15:45:43 - 07-Apr-25
Sell* 1,358 169.275p Ordinary
15:43:03 - 07-Apr-25
Buy* 132 174.70p Ordinary
15:24:05 - 07-Apr-25
Buy* 452 174.70p Ordinary
15:17:18 - 07-Apr-25
Buy* 112 174.00p Ordinary
11:43:04 - 07-Apr-25
Buy* 2 174.03p Ordinary
11:19:28 - 07-Apr-25
Sell* 750 165.8373p Ordinary
10:28:21 - 07-Apr-25
Sell* 2 165.62p Ordinary
10:22:28 - 07-Apr-25
Buy* 1,200 169.5967p Ordinary
10:17:06 - 07-Apr-25
Buy* 650 169.50p Automatic Execution
10:12:53 - 07-Apr-25
See more Hemogenyx trades

Hemogenyx (HEMO) Share Price History

Time period:
to
Date Open High Low Close Volume
7th Apr 2025 (Mon) 180.00 180.00 165.50 169.75 33,614
4th Apr 2025 (Fri) 189.00 189.00 185.00 184.25 12,050
3rd Apr 2025 (Thu) 189.00 189.00 189.00 190.75 2,507
2nd Apr 2025 (Wed) 197.50 197.50 189.50 193.75 18,837
1st Apr 2025 (Tue) 189.02 189.02 189.02 193.50 5,495
31st Mar 2025 (Mon) 198.00 198.00 189.50 193.50 12,593
28th Mar 2025 (Fri) 182.50 197.50 182.50 193.75 14,733
27th Mar 2025 (Thu) 195.00 197.00 195.00 191.25 5,087
26th Mar 2025 (Wed) 190.25 191.25 190.25 191.25 7,597
25th Mar 2025 (Tue) 192.00 192.00 192.00 190.25 24,254
24th Mar 2025 (Mon) 182.50 190.00 182.50 186.25 22,373
21st Mar 2025 (Fri) 180.00 186.50 180.00 180.25 81,162
20th Mar 2025 (Thu) 168.50 168.50 168.50 175.25 13,487
19th Mar 2025 (Wed) 178.00 178.00 160.00 171.75 65,729
18th Mar 2025 (Tue) 180.00 180.00 180.00 183.75 71,707
17th Mar 2025 (Mon) 189.50 189.50 189.50 184.75 69,565
14th Mar 2025 (Fri) 199.50 199.50 175.00 177.25 16,162
13th Mar 2025 (Thu) 184.00 199.50 182.00 183.00 51,588
12th Mar 2025 (Wed) 200.00 200.00 184.00 186.75 124,551
11th Mar 2025 (Tue) 210.00 210.00 192.00 196.50 712,909
10th Mar 2025 (Mon) 320.00 320.00 320.00 305.50 10,044
See more Hemogenyx price history

Hemogenyx (HEMO) Regulatory News

Date Source Headline
3rd Apr 2025 7:00 am RNS-R FDA Annual Report
31st Mar 2025 7:00 am RNS Total Voting Rights
24th Mar 2025 7:00 am RNS First Patient Safety
17th Mar 2025 7:00 am RNS Recruitment of Second Patient for Clinical Trials
13th Mar 2025 3:10 pm RNS Conversion of convertible loan notes
11th Mar 2025 7:00 am RNS Institutional investment
24th Feb 2025 7:00 am RNS First-in-Human Treatment with HG-CT-1
19th Feb 2025 4:50 pm RNS Issue of convertible loan notes
31st Jan 2025 9:35 am RNS Total Voting Rights
8th Jan 2025 7:00 am RNS Placing to raise £340,000
See more Hemogenyx regulatory news

Hemogenyx (HEMO) Share News

TRADING UPDATES: Golden Rock secures refinancing; tinyBuild makes sale

4th Apr 2025 19:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Hemogenyx administers first human dose for leukemia therapy

24th Feb 2025 11:06

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Administers its first in-human dose of HG-CT-1, the firm's proprietary CAR-T cell therapy, used in the treatment of relapsed or refractory acute myeloid leukemia in adults. Says further updates on the clinical trial will be provided "in due course". Read More

IN BRIEF: Hemogenyx Pharmaceuticals raises GBP340,000 for drug trial

8th Jan 2025 11:49

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Says it has raised GBP340,000 through the placing of 100,000 shares at 340p each. The financing will be dedicated to the clinical trial of its HG-CT-1 drug, which is used for treatment of acute myeloid leukaemia in adults. The first patient for the trial has been recruited and is being tested to ensure they satisfy the clinic protocol. Read More

Hemogenyx opens first clinical site for leukaemia therapy trial

30th Dec 2024 12:01

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday reported the opening of the first clinical site in its HG-CT-1 phase 1 trial. Read More

TRADING UPDATES: SDX plots AIM exit; Celadon receives funds

6th Dec 2024 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more Hemogenyx news
FTSE 100 Latest
Value7,702.08
Change-352.90

Login to your account

Forgot Password?

Not Registered